Drug Target Review

SEPTEMBER 11, 2024

How does morADC technology combine the properties of small molecules and monoclonal antibodies to enhance anti-aggregation effects for CNS applications? The morADC are able to cross the blood-brain barrier more efficiently and offer higher potency than individual parent molecules.

Small Molecule 52

Small Molecule Disease Therapies Drugs 52

NIH Director's Blog: Drug Development

MAY 21, 2020

One advantage of this class of therapeutics is that the timelines for their development, testing, and approval are typically shorter than those for drugs made of chemical compounds, called small molecules. In the U.S.

Virus 52

Virus Vaccine Laboratories Science 52

The Pharma Data

DECEMBER 15, 2020

We believe this small molecule platform has the potential beyond actinic keratosis and are leveraging the platform to develop therapies for other oncology indications.”. Founded in 2003, Athenex, Inc. Mr. Peter Guenter, CEO of Almirall, stated, “We are delighted to partner with Athenex to market Klisyri in the U.S.

FDA Approval 52

FDA Approval Treatment FDA Therapies 52

The Pharma Data

NOVEMBER 5, 2020

Prior to that, Taveras was vice president of Small Molecule Drug Discovery and CMC Development at Biogen Idec, and Alantos Pharmaceuticals, which was acquired by Amgen in 2007. Sussman has also had leadership experience in industry as the founder and vice president of both Amphioxus Cell Technologies from 1995 to 2003 and Hepatix, Inc.

Analytical Chemistry 40

Analytical Chemistry Pharmaceuticals Small Molecule Therapies 40

New Drug Approvals

JULY 10, 2023

1] Zavegepant is an antagonist of the calcitonin gene-related peptide (CGRP) receptor currently in phase 3 trials in an intranasal formulation for the treatment of migraine. The clinical trial is expected to complete in September 2020. Zavegepant is indicated for the acute treatment of migraine with or without aura in adults. [1]

Clinical Trials 40

Clinical Trials Treatment Trials FDA 40

Drug Target Review

MARCH 26, 2025

Cannot use the same patch site for 7 days, due to blistering 9 , 13 Gel AndroGel 2003 Ease of use, non-invasive, less skin irritation compared to patches. It subsequently demonstrated promise for the administration of peptides, monoclonal antibodies and small molecules. Endocr Connect. 2022;11(8):e220112. [15] 15] Keown A.

Therapies 52

Therapies Compliance Treatment Small Molecule 52